Compare Northern Trust Corporation Common Stock (NTRS) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northern Trust Corporation Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Northern Trust Corporation Common Stock trades at $162.48 (market cap $30.63B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Northern Trust Corporation Common Stock is far larger — about 5.9× Oruka Therapeutics Inc. Common Stock's market cap, and Northern Trust Corporation Common Stock pays a 1.96% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northern Trust Corporation Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| NTRS | ORKA | |
|---|---|---|
Market Cap | $30.63B | $5.18B |
Volume | 964,550 | 490,798 |
Sector | Financials | Health |
52-Week High | $191.47 | $113.08 |
52-Week Low | $122.72 | $26.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | -$5.35B | $4.31B |
Dividend Yield | 1.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Northern Trust Corporation Common Stock
Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
